skip to Main Content
Conferences

Asembia's Specialty
Pharmacy Summit

Sarah Alwardt

“As the specialty pharmacy market becomes increasingly competitive, having clear conversations on defining value from the patient perspective is imperative.”

Sarah Alwardt
Senior Vice President

Join our experts, Lance Grady, Neil Lund, and Ryan Urgo as they close out the conference by speaking about the outlook for healthcare reform in 2022, potential congressional and administrative activity, stakeholder implications, and strategy considerations during the session:

“Evolution of Biden’s Healthcare Agenda in an Election Year” on Wednesday, May 4, 3 PM PT

Hear Our Perspective

Tune in to the 3-minute videos below for key highlights on navigating patient-centered opportunities and how specialty pharmacies are engaging with manufacturers and payers to help provide better care management, greater adherence, and improved retention activities.

Learn about how patient support services in specialty pharmacy can help patients through their journey. We’ll cover the evolving coverage landscape, the impacts of medication affordability, copay accumulators and copay maximizers, free drug programs, and growth in wraparound services.

Explore the ways that today’s specialty pharmacies act as intermediaries with manufacturers and payers helping patients with rare or complex diseases achieve better outcomes.

Hear more on the state of the Biden administration’s healthcare agenda in an election year and its impact on stakeholders, especially with Medicare Part D.

Meet Our
Experts

The Avalere experts below will attend the Asembia conference this year. Click the button to the right to connect with them and see how Avalere can help your business.

Jessica AlessioJessica Alessio

Associate Principal
Market Access & Reimbursement

Sarah AlwardtSarah Alwardt

Senior Vice President
Center for Healthcare Transformation

Lance GradyLance Grady

Practice Director
Market Access & Reimbursement

Mark GoodingMark Gooding

Principal
Market Access & Reimbursement

Omar HafezOmar Hafez

Managing Director
Market Access & Reimbursement

Michael KearneyMichael Kearney

Associate Principal
Market Access & Reimbursement

Neil LundNeil Lund

Senior Advisor
Market Access & Reimbursement

John C. NealJohn C. Neal

Managing Director
Market Access & Reimbursement

Ryan UrgoRyan Urgo

Managing Director
Policy

Megan WestMegan West

Principal
Policy

Our experts will be available to discuss these priority topics

Maximizing Payer Engagement

Top-tier payer engagement is built upon an intimate knowledge of payer incentives and decision making and an understanding of how to add value beyond rebating.

US Drug Pricing Policy and Regulatory Interventions

Despite being an election year, Congress still has the incentive and time to pass drug pricing legislation. Additionally, the Biden administration will likely advance drug pricing priorities through regulatory means.

Patient-Centric Evidence Development

Increasingly, payers and providers are demanding non-traditional evidence to answer questions about how different types of patients fare in real-world treatment settings.

Back To Top